CD274 and liver cancer: NK cells modified with TLS11a aptamer and programmed cell death ligand 1 (PD-L1) aptamer can both target attacking liver cancer cells and resist the inhibition of PD-1/PD-L1 immune checkpoint, enhancing the immunotherapeutic efficacy of NK cells in solid tumors 205.